

PHARMACEUTICAL 2023

Phathom Pharmaceuticals Inc. Rank 382 of 446









PHARMACEUTICAL 2023



Phathom Pharmaceuticals Inc. Rank 382 of 446

The relative strengths and weaknesses of Phathom Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 16% points. The greatest weakness of Phathom Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is -161%, being 205% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	160,512
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,237
Liabilities, Non-Current	103,862
Other Assets	3,091
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	109,525
Other Net Income	-25,283
Other Revenues	0
Property and Equipment	1,207
Research and Development	71,441
Selling, General and Administrative Expense	100,999

Output Variable	Value in 1000 USD
Assets	164,810
Liabilities	239,624
Expenses	172,440
Revenues	0
Stockholders Equity	-74,814
Net Income	-197,723
Comprehensive Net Income	-197,723
Economic Capital Ratio	-161%

